Sandra Silberman, MD
Enriched profileManaging Partner, SLS Oncology LLC (Durham, NC), per Crunchbase · Hematology / Oncology
Sandra Silberman is Managing Partner, SLS Oncology LLC (Durham, NC), per Crunchbase. ClinicalTrials.gov lists 6 registered studies with this person as an investigator.
Data verified 25 Oct 2026
Overview
Updated 27 Oct 2026
Sandra Silberman, MD PHD, is Managing Partner, SLS Oncology LLC (Durham, NC), per Crunchbase. The public record shows 64 publications with 13,588 citations (h-index 18), centered on Lymphoma, Breast Cancer, Hodgkin Disease. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 1 companies.
- Top research focus: Lymphoma
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 1 companies
Generated from the cited public record · current as of 27 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 26 Oct 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
Sponsor: CNS Pharmaceuticals, Inc.
- Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)
Sponsor: Moleculin Biotech, Inc.
- A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer
Sponsor: Cortice Biosciences, Inc.
Industry payments
Updated 26 Oct 2026
1 company reported payments to CMS in program years 2023–2023. These are public disclosures, not judgments. The latest:
- Telix PharmaceuticalsProgram year20231 payment
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Background & recognition
Updated 26 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →everydayhealth.care ↗
- PhD in Tumor Immunology
Johns Hopkins University
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →crunchbase.com ↗ - MD
Cornell University Medical College
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →crunchbase.com ↗
Secondary affiliations
appointments beyond the home institution- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →1stoncology.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthmanagement.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Seth Steinberg, PhD
National Cancer Institute (NCI)
Gilles Salles
Memorial Sloan Kettering Cancer Center
Thomas Witzig, MD
Mayo Clinic
Wyndham Wilson, MD
National Cancer Institute (NCI)